Coq and Ranexa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Coq (coenzyme q - 10) and Ranexa (ranolazine). Common drug interactions include neck pain among females and constipation among males.

The phase IV clinical study analyzes what interactions people have when they take Coq and Ranexa. It is created by eHealthMe based on reports of 79 people who take the same drugs from the FDA, and is updated regularly.

What is Coq?

Coq has active ingredients of coenzyme q - 10. It is often used in high blood cholesterol. eHealthMe is studying from 11,467 Coq users. Check the latest studies of Coq.

What is Ranexa?

Ranexa has active ingredients of ranolazine. It is often used in angina. eHealthMe is studying from 11,758 Ranexa users. Check the latest studies of Ranexa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 17, 2026

79 people who take Coq and Ranexa together, and have interactions are studied.

What are the common drug interactions of Coq and Ranexa, by gender? *:

female:

Neck pain
Sinusitis (inflammation of sinus)
Blood immunoglobulin g decreased
Dyspnoea (difficult or laboured respiration)
Enteritis infectious (infection with feline parvovirus (fpv), also known as feline panleucopenia virus)
Feeling cold
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Headache (pain in head)
Herpes zoster
Infection

male:

Constipation
Dizziness
Blood glucose increased
Blood pressure decreased
Contusion (a type of hematoma of tissue in which capillaries)
Cough
Diarrhoea
Dyskinesia (abnormality or impairment of voluntary movement)
Dyspepsia (indigestion)
Fatigue (feeling of tiredness)

What are the common drug interactions of Coq and Ranexa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
Drug hypersensitivity
Injection site pruritus (severe itching at injection site)
Injection site reaction
Injection site swelling
Urticaria (rash of round, red welts on the skin that itch intensely)

50-59:

Coronary arterial stent insertion
Cough
Decreased activity
Dizziness
Electrocardiogram qt prolonged
Hypoaesthesia (reduced sense of touch or sensation)
Influenza like illness
Insomnia (sleeplessness)
Neuropathy peripheral (surface nerve damage)
Pain

60+:

Dizziness
Feeling hot
Fatigue (feeling of tiredness)
Infusion site haemorrhage (bleeding from infusion site)
Malaise (a feeling of general discomfort or uneasiness)
Nausea (feeling of having an urge to vomit)
Neck pain
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Sinusitis (inflammation of sinus)
Visual impairment

What are the existing conditions these people have? *

Stable Angina (a constant chest pain): 8 people, 10.13%
High Blood Pressure: 7 people, 8.86%
Hyperkalemia (damage to or disease of the kidney): 6 people, 7.59%
Cardiac Disorder: 6 people, 7.59%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 6 people, 7.59%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 4 people, 5.06%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 5.06%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 5.06%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 5.06%
Diabetes: 4 people, 5.06%

* Approximation only. Some reports may have incomplete information.

Do you take Coq and Ranexa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously